UCB’s Vimpat Gets FDA Approval For Epileptic Seizures
This article was originally published in The Pink Sheet Daily
Executive Summary
Belgian specialty pharma hopes to launch drug in U.S. early next year; says blockbuster sales could follow.
You may also be interested in...
China's Epilepsy Market Growing Rapidly; Attracting More Multinational Companies
SHANGHAI - The Chinese anti-epilepsy drug market is expected to grow at an annual rate of roughly 30 percent in coming years, and multinational companies account for most of that market share, healthcare analysts predict
FDA Opts For MedGuide, Not Black Box For Anti-Epileptic Suicidality
FDA has made a decision on how to communicate the suicidality risk for anti-epileptic drugs: with the first novel approvals in that class since an advisory committee on the topic, FDA has opted for a Medication Guide over a "black box" warning
FDA Opts For MedGuide, Not Black Box For Anti-Epileptic Suicidality
FDA has made a decision on how to communicate the suicidality risk for anti-epileptic drugs: with the first novel approvals in that class since an advisory committee on the topic, FDA has opted for a Medication Guide over a "black box" warning